Publications
157
Citations
2,694
Est. group size
~35
Recurring co-author estimate
Active years
25
Publishing since 2002
Typically publishes in teams of ~19 · 7% small-team papers (≤3 authors) · across 5 venues
- A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
Future Oncology · 2025
- Clinical, environmental, genetic, and genomic profile of patients with rapid progression to metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology · 2025
- Supplementary Data 1 from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Data from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Supplementary Data 1 from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Supplementary Data 1 from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Data from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Data from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Supplementary Data 1 from Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
2024
- Clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer: A final report.
Journal of Clinical Oncology · 2024
- TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Annals of Oncology · 2024
- Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Clinical Cancer Research · 2024
- TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
Journal of Clinical Oncology · 2024
- A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer
Future Oncology · 2024
- A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.
Journal of Clinical Oncology · 2023
- Journal of Clinical Oncology×23
- Clinical Cancer Research×11
- Cancer Research×5
- Annals of Oncology×3
- European Urology×3
- Ajjai Alva
Medicine · University of Michigan
- Debasish Sundi
Medicine · The Ohio State University
- Irene Tsung
Medicine · University of Michigan
- Amir Mortazavi
Medicine · The Ohio State University
- Ahmad Shabsigh
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile